Regeneron (REGN) Reports Q1 Earnings: What Key Metrics Have to Say

For the quarter ended March 2024, Regeneron (REGN) reported revenue of $3.15 billion, down 0.5% over the same period last year. EPS came in at $9.55, compared to $10.09 in the year-ago quarter.

The reported revenue represents a surprise of -1.53% over the Zacks Consensus Estimate of $3.19 billion. With the consensus EPS estimate being $10.20, the EPS surprise was -6.37%.

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.

Here is how Regeneron performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

  • Revenues- Eylea (Aflibercept)- US: $1.40 billion versus $1.33 billion estimated by five analysts on average. Compared to the year-ago quarter, this number represents a -2.3% change.
  • Revenues- Praluent (alirocumab)- US: $70 million versus $41.30 million estimated by five analysts on average. Compared to the year-ago quarter, this number represents a +75% change.
  • Revenues- Kevzara (sarilumab)- ROW: $44.10 million versus the four-analyst average estimate of $41.34 million. The reported number represents a year-over-year change of +12.2%.
  • Revenues- Dupixent (dupilumab)- US: $2.22 billion versus the four-analyst average estimate of $2.35 billion. The reported number represents a year-over-year change of +16.9%.
  • Revenues- Net product sales: $1.76 billion versus $1.74 billion estimated by eight analysts on average. Compared to the year-ago quarter, this number represents a +5.6% change.
  • Revenues- Collaboration: $1.27 billion compared to the $1.32 billion average estimate based on seven analysts. The reported number represents a change of -8.1% year over year.
  • Revenues- Other Revenue: $116.90 million compared to the $111.01 million average estimate based on seven analysts. The reported number represents a change of +0.8% year over year.
  • Total Sanofi collaboration revenue: $910 million versus $946.50 million estimated by six analysts on average.
  • Total Bayer collaboration revenue: $356 million versus $377.86 million estimated by six analysts on average.
  • Revenues- Libtayo- Total: $263.90 million compared to the $262.40 million average estimate based on four analysts. The reported number represents a change of +44.5% year over year.
  • Revenues- Dupixent (dupilumab)- Total: $3.08 billion versus $3.10 billion estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +23.8% change.
  • Revenues- Kevzara (sarilumab)- Total: $94.10 million compared to the $89.98 million average estimate based on four analysts. The reported number represents a change of +19.9% year over year.
View all Key Company Metrics for Regeneron here>>>

Shares of Regeneron have returned -5% over the past month versus the Zacks S&P 500 composite's -4.2% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.

7 Best Stocks for the Next 30 Days

Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops."

Since 1988, the full list has beaten the market more than 2X over with an average gain of +24.2% per year. So be sure to give these hand picked 7 your immediate attention. 

See them now >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Regeneron Pharmaceuticals, Inc. (REGN) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Tags

More Related Articles

Info icon

This data feed is not available at this time.

Sign up for the TradeTalks newsletter to receive your weekly dose of trading news, trends and education. Delivered Wednesdays.